Focal therapy for localized prostate cancer: the “state of the art”

In a report on the UroToday web site, John Fortin, a prostate cancer patient who chose to have focal therapy himself a while ago, has reported on information presented at the 12th International Symposium on Focal Therapy and Imaging in Prostate and Kidney Cancer, which was held in Washington, DC, in February this year. … READ MORE …

Symptom management after initial prostate cancer treatment

A recently published study has provided us with interesting information on how patients can be taught to better “self-manage” post-treatment, problematic symptoms associated with first-line treatment of localized prostate cancer. … READ MORE …

“Long-term” data on FLA in the treatment of localized prostate cancer

An important new paper in the Journal of Vascular and Interventional Radiology has just provided us with the first large set of data on the outcomes of men with prostate cancer treated with focal laser ablation (FLA). … READ MORE …

Effects of prazosin + radiation therapy on recurrence-free survival

The following was brought to our attention by Arthur as a consequence of a question posed on Ask Arthur by a reader within the past 24 hours. … READ MORE …

Updated PIVOT data seem to support recent AUA/ASTRO/SUO guidelines

A new article in this week’s New England Journal of Medicine has given us follow-up data from the PIVOT trial of radical prostatectomy vs. simple observation in treatment of localized prostate cancer. … READ MORE …

ADT + radiation therapy in men with high-risk prostate cancer

So one of the more important papers that will be presented at the ASCO meeting in Chicago today will give us the 10-year results of the Canadian PCS IV trial. … READ MORE …

New guidance on treatment of localized prostate cancer from AUA and others

Over the weekend, the American Urological Association (AUA), together with the Society for Urologic Oncology (SUO), and the American Society for Radiation Oncology (ASTRO) issued new guidance on the treatment of localized prostate cancer. … READ MORE …

Decision making and the treatment of localized prostate cancer today

This month’s issue of Urologic Oncology contains a series of six articles that may be of particular interest to prostate cancer support group leaders and other prostate cancer educators. … READ MORE …

Does adding an aspirin improve outcomes to treatment for localized prostate cancer?

The clinical research community in the UK (with access to relevant government funding) still appears to be able to do the types of trial of older drugs that would rarely if ever get done here in America today. … READ MORE …

Formal comment from ASTRO on the results of the ProtecT trial

The following official statement was issued on September 15 by the American Society for Radiation Oncology (ASTRO): … READ MORE …

Alas, … the surgery vs. radiation therapy war continues …

In what certainly appears to be the largest and most thorough meta-analysis published to date, the authors conclude that surgery is a more effective first-line treatment for localized prostate cancer than radiation therapy. However, … READ MORE …

A rise in the incidence of metastatic prostate cancer from 2004 to 2013

A newly published article in the journal Prostate Cancer and Prostatic Diseases suggests that there has been a relative 72 percent rise in the incidence of metastatic prostate cancer from 2004 to 2013 — mostly among men of 55 to 69 years of age. … READ MORE …

New form of vaccine therapy — for low-risk prostate cancer

According to a media report on the MarketWatch web site, a company called OncBioMune is to initiate Phase II clinical trials of a new type of prostate cancer vaccine (ProscaVax). … READ MORE …

Life expectancy, mortality, surgery, risk, and management of localized prostate cancer

A critical factor in understanding why non-treatment (i.e., monitoring with either active surveillance or watchful waiting) may be a better idea than immediate treatment for men with localized prostate cancer has to do with risk of death from causes other than the cancer. … READ MORE …

Neoadjuvant chemotherapy prior to surgery in higher-risk patients

A combined Russian and German research team has provided some interesting preliminary information on the use of neoadjuvant, low-dose docetaxel-based chemotherapy in treatment of intermediate- and high-risk patients prior to radical prostatectomy. … READ MORE …